To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.
From the management of primary immunodeficiency to the control of autoimmune and inflammatory conditions, Ig therapy has a wide range of indications. The Interlaken Leadership Awards program was created to identify new clinical applications for polyvalent immunoglobulins for potential further clinical investigation, with the ultimate goal of having a positive impact on the quality of life for people who are managing neurological conditions, such as Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease and multiple sclerosis.
“Recent research has highlighted several promising novel applications for polyvalent immunoglobulin therapy that align with the commitment CSL Behring has to saving lives and improving the quality of life for people with rare and serious disorders," said Jeffrey Baggish, M.D., Director of Medical Affairs, Immunology & Pulmonary at CSL Behring. “CSL Behring is proud to support investigators who are devoted to improving patient outcomes by advancing the evolving science behind Ig therapy."
Comprehensive information about the Interlaken Leadership Awards is available on the grant program’s web site, www.InterlakenLeadershipAwards.com. This website was developed as a single resource for information pertaining to the grant program and application process.
Any individual actively engaged in clinical or basic research in a field of study consistent with the goals of the Interlaken Leadership Awards program is eligible.
For more information and to apply for the Interlaken Leadership Awards, please visit www.InterlakenLeadershipAwards.com.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and inherited respiratory disease. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.